Allogeneic single-donor cryoseal produced from fresh-frozen quarantine apheresis plasma as alternative for multidonor or autologous fibrin sealants

Transfusion

Volumn 52, Issue 3, 2012, Pages 517-523

  Hazelaar, Sandra ^a   Dijkstra Tiekstra, Margriet J ^a   De Korte, Dirk ^a   De Wildt Eggen, Janny ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC CRYOSEAL; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; FIBRIN GLUE; FIBRINOGEN; FRESH FROZEN PLASMA; PLASMINOGEN; THROMBIN; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; BLOOD CLOTTING TIME; CRYOPRECIPITATE; DEVICES; HUMAN; PROTEIN ANALYSIS; QUALITY CONTROL;

BIOENGINEERING; BLOOD DONORS; FIBRIN TISSUE ADHESIVE; HEMOSTATICS; HUMANS; ISOANTIGENS; PLASMA; PLASMAPHERESIS; QUALITY CONTROL;

EID: 84858299013     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03315.x     Document Type: Article

References (23)

1. Janmey PA, Winer JP, Weisel JW,. Fibrin gels and their clinical and bioengineering applications. J R Soc Interface 2009; 6: 1-10.
2. Mintz PD, Mayers L, Avery N, Flanagan HL, Burks SG, Spotnitz WD,. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center. Ann Clin Lab Sci 2001; 31: 108-18. (Pubitemid 32097219)
3. Radosevich M, Goubran HA, Burnouf T,. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997; 72: 133-43. (Pubitemid 27187368)
4. Carless PA, Anthony DM, Henry DA,. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg 2002; 89: 695-703. (Pubitemid 34595693)
5. Tredree R, Beierlein W, Debrix I, Eisert A, Goffredo F, Gõmez de Salazar E, Rambourg P, Saint-Remy JM, Sturm C, Watson N,. Evaluating the differences between fibrin sealants: recommendations from an international advisory panel of hospital pharmacists. EJHP Sci 2006; 12: 3-9.
6. Oswald AM, Joly LM, Gury C, Disdet M, Leduc V, Kanny G,. Fatal intraoperative anaphylaxis related to aprotinin after local application of fibrin glue. Anesthesiology 2003; 99: 762-3. (Pubitemid 37052003)
7. Kober BJ, Scheule AM, Voth V, Deschner N, Schmid E, Ziemer G,. Anaphylactic reaction after systemic application of aprotinin triggered by aprotinin-containing fibrin sealant. Anesth Analg 2008; 107: 406-9.
8. Schlag MG, Hopf R, Redl H,. Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. Neurosurgery 2000; 47: 1463-7.
9. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H,. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301: 168-73. (Pubitemid 34256345)
10. Evatt B, Austin H, Leon G, Ruiz-Saez A, de Bosch N,. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 2000; 6: 128-32. (Pubitemid 30468304)
11. Jackson MR,. Fibrin sealants in surgical practice: an overview. Am J Surg 2001; 182: 1S-7S. (Pubitemid 32898601)
12. Kawamura M, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K,. Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg 2002; 73: 1098-100. (Pubitemid 34275886)
13. Buchta C, Dettke M, Funovics PT, Höker P, Knöher M, Quehenberger P, Treitl C, Worel N,. Fibrin sealant produced by the CryoSeal FS system: product chemistry, material properties and possible preparation in the autologous preoperative setting. Vox Sang 2004; 86: 257-62. (Pubitemid 38902097)
14. Buchta C, Hedrich HC, Macher M, Höker P, Redl H,. Biochemical characterization of autologous fibrin sealants produced by CryoSeal® and Vivostat® in comparison to the homologous fibrin sealant product Tissucol/Tisseel®. Biomaterials 2005; 26: 6233-41. (Pubitemid 40826992)
15. Health Council of the Netherlands. Bloodproducts and parvovirus B19. Health Council of the Netherlands 2002; Publication no. 2002-07.
16. Rock G, Neurath D, Semple E, Harvey M, Freedman M,. Preparation and characterization of human thrombin for use in a fibrin glue. Transfus Med 2007; 17: 187-91. (Pubitemid 46897119)
17. Rock G, Berger R, Lange J, Tokessy M, Palmer DS, Giulivi A,. A novel, automated method of temperature cycling to produce cryoprecipitate. Transfusion 2001; 41: 232-5. (Pubitemid 32220515)
18. Beierlein W, Scheule AM, Dietrich W, Ziemer G,. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005; 79: 741-8. (Pubitemid 40186610)
19. Furst W, Banerjee A, Redl H,. Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin. J Biomed Mater Res B Appl Biomater 2007; 82: 109-14. (Pubitemid 47015359)
20. Marx G, Mou X,. Characterizing fibrin glue performance as modulated by heparin, aprotinin, and factor XIII. J Lab Clin Med 2002; 140: 152-60.
21. Krishnan LK, Vijayan LA, Uma Shankar PR, Mohanty M,. Fibrinolysis inhibitors adversely affect remodeling of tissues sealed with fibrin glue. Biomaterials 2003; 24: 321-7. (Pubitemid 35292576)
22. Kheirabadi BS, Pearson R, Tuthill D, Rudnicka K, Holcomb JB, Drohan W, MacPhee MJ,. Comparative study of the hemostatic efficacy of a new human fibrin sealant: is an antifibrinolytic agent necessary? J Trauma 2002; 52: 1107-15. (Pubitemid 34664385)
23. Franceschi D, Livingstone A, Choti M, Busuttil RW, D'Angelica M, Sher LS, Madsen T, Kumar V,. Evaluation of an autologous fibrin sealant in patients undergoing liver resections: a multicenter randomized clinical trial. HPB 2007; 9: 78.